Interventions to increase COVID-19 vaccine uptake: a scoping review.


Journal

The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747

Informations de publication

Date de publication:
03 08 2022
Historique:
entrez: 3 8 2022
pubmed: 4 8 2022
medline: 6 8 2022
Statut: epublish

Résumé

Vaccines are effective in preventing severe COVID-19, a disease for which few treatments are available and which can lead to disability or death. Widespread vaccination against COVID-19 may help protect those not yet able to get vaccinated. In addition, new and vaccine-resistant mutations of SARS-CoV-2 may be less likely to develop if the spread of COVID-19 is limited. Different vaccines are now widely available in many settings. However, vaccine hesitancy is a serious threat to the goal of nationwide vaccination in many countries and poses a substantial threat to population health. This scoping review maps interventions aimed at increasing COVID-19 vaccine uptake and decreasing COVID-19 vaccine hesitancy. To scope the existing research landscape on interventions to enhance the willingness of different populations to be vaccinated against COVID-19, increase COVID-19 vaccine uptake, or decrease COVID-19 vaccine hesitancy, and to map the evidence according to addressed populations and intervention categories. We searched Cochrane COVID-19 Study Register, Web of Science (Science Citation Index Expanded and Emerging Sources Citation Index), WHO COVID-19 Global literature on coronavirus disease, PsycINFO, and CINAHL to 11 October 2021. We included studies that assess the impact of interventions implemented to enhance the willingness of different populations to be vaccinated against COVID-19, increase vaccine uptake, or decrease COVID-19 vaccine hesitancy. We included randomised controlled trials (RCTs), non-randomised studies of intervention (NRSIs), observational studies and case studies with more than 100 participants. Furthermore, we included systematic reviews and meta-analyses. We did not limit the scope of the review to a specific population or to specific outcomes assessed. We excluded interventions addressing hesitancy towards vaccines for diseases other than COVID-19. Data were analysed according to a protocol uploaded to the Open Science Framework. We used an interactive scoping map to visualise the results of our scoping review. We mapped the identified interventions according to pre-specified intervention categories, that were adapted to better fit the evidence. The intervention categories were: communication interventions, policy interventions, educational interventions, incentives (both financial and non-financial), interventions to improve access, and multidimensional interventions. The study outcomes were also included in the mapping. Furthermore, we mapped the country in which the study was conducted, the addressed population, and whether the design was randomised-controlled or not. We included 96 studies in the scoping review, 35 of which are ongoing and 61 studies with published results. We did not identify any relevant systematic reviews. For an overview, please see the interactive scoping map (https://tinyurl.com/2p9jmx24) STUDIES WITH PUBLISHED RESULTS Of the 61 studies with published results, 46 studies were RCTs and 15 NRSIs. The interventions investigated in the studies were heterogeneous with most studies testing communication strategies to enhance COVID-19 vaccine uptake. Most studies assessed the willingness to get vaccinated as an outcome. The majority of studies were conducted in English-speaking high-income countries. Moreover, most studies investigated digital interventions in an online setting. Populations that were addressed were diverse. For example, studies targeted healthcare workers, ethnic minorities in the USA, students, soldiers, at-risk patients, or the general population.  ONGOING STUDIES Of the 35 ongoing studies, 29 studies are RCTs and six NRSIs. Educational and communication interventions were the most used types of interventions. The majority of ongoing studies plan to assess vaccine uptake as an outcome. Again, the majority of studies are being conducted in English-speaking high-income countries. In contrast to the studies with published results, most ongoing studies will not be conducted online. Addressed populations range from minority populations in the USA to healthcare workers or students. Eleven ongoing studies have estimated completion dates in 2022.   AUTHORS' CONCLUSIONS: We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research. We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research.

Sections du résumé

BACKGROUND
Vaccines are effective in preventing severe COVID-19, a disease for which few treatments are available and which can lead to disability or death. Widespread vaccination against COVID-19 may help protect those not yet able to get vaccinated. In addition, new and vaccine-resistant mutations of SARS-CoV-2 may be less likely to develop if the spread of COVID-19 is limited. Different vaccines are now widely available in many settings. However, vaccine hesitancy is a serious threat to the goal of nationwide vaccination in many countries and poses a substantial threat to population health. This scoping review maps interventions aimed at increasing COVID-19 vaccine uptake and decreasing COVID-19 vaccine hesitancy.
OBJECTIVES
To scope the existing research landscape on interventions to enhance the willingness of different populations to be vaccinated against COVID-19, increase COVID-19 vaccine uptake, or decrease COVID-19 vaccine hesitancy, and to map the evidence according to addressed populations and intervention categories.
SEARCH METHODS
We searched Cochrane COVID-19 Study Register, Web of Science (Science Citation Index Expanded and Emerging Sources Citation Index), WHO COVID-19 Global literature on coronavirus disease, PsycINFO, and CINAHL to 11 October 2021.
SELECTION CRITERIA
We included studies that assess the impact of interventions implemented to enhance the willingness of different populations to be vaccinated against COVID-19, increase vaccine uptake, or decrease COVID-19 vaccine hesitancy. We included randomised controlled trials (RCTs), non-randomised studies of intervention (NRSIs), observational studies and case studies with more than 100 participants. Furthermore, we included systematic reviews and meta-analyses. We did not limit the scope of the review to a specific population or to specific outcomes assessed. We excluded interventions addressing hesitancy towards vaccines for diseases other than COVID-19.
DATA COLLECTION AND ANALYSIS
Data were analysed according to a protocol uploaded to the Open Science Framework. We used an interactive scoping map to visualise the results of our scoping review. We mapped the identified interventions according to pre-specified intervention categories, that were adapted to better fit the evidence. The intervention categories were: communication interventions, policy interventions, educational interventions, incentives (both financial and non-financial), interventions to improve access, and multidimensional interventions. The study outcomes were also included in the mapping. Furthermore, we mapped the country in which the study was conducted, the addressed population, and whether the design was randomised-controlled or not.
MAIN RESULTS
We included 96 studies in the scoping review, 35 of which are ongoing and 61 studies with published results. We did not identify any relevant systematic reviews. For an overview, please see the interactive scoping map (https://tinyurl.com/2p9jmx24) STUDIES WITH PUBLISHED RESULTS Of the 61 studies with published results, 46 studies were RCTs and 15 NRSIs. The interventions investigated in the studies were heterogeneous with most studies testing communication strategies to enhance COVID-19 vaccine uptake. Most studies assessed the willingness to get vaccinated as an outcome. The majority of studies were conducted in English-speaking high-income countries. Moreover, most studies investigated digital interventions in an online setting. Populations that were addressed were diverse. For example, studies targeted healthcare workers, ethnic minorities in the USA, students, soldiers, at-risk patients, or the general population.  ONGOING STUDIES Of the 35 ongoing studies, 29 studies are RCTs and six NRSIs. Educational and communication interventions were the most used types of interventions. The majority of ongoing studies plan to assess vaccine uptake as an outcome. Again, the majority of studies are being conducted in English-speaking high-income countries. In contrast to the studies with published results, most ongoing studies will not be conducted online. Addressed populations range from minority populations in the USA to healthcare workers or students. Eleven ongoing studies have estimated completion dates in 2022.   AUTHORS' CONCLUSIONS: We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research.
AUTHORS CONCLUSIONS
We were able to identify and map a variety of heterogeneous interventions for increasing COVID-19 vaccine uptake or decreasing vaccine hesitancy. Our results demonstrate that this is an active field of research with 61 published studies and 35 studies still ongoing. This review gives a comprehensive overview of interventions to increase COVID-19 vaccine uptake and can be the foundation for subsequent systematic reviews on the effectiveness of interventions to increase COVID-19 vaccine uptake.  A research gap was shown for studies conducted in low and middle-income countries and studies investigating policy interventions and improved access, as well as for interventions addressing children and adolescents. As COVID-19 vaccines become more widely available, these populations and interventions should not be neglected in research.

Identifiants

pubmed: 35920693
doi: 10.1002/14651858.CD015270
pmc: PMC9347311
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

CD015270

Informations de copyright

Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Références

Anaesth Crit Care Pain Med. 2021 Jun;40(3):100860
pubmed: 33848874
Health Commun. 2022 Jul;37(8):944-951
pubmed: 33499677
PLoS One. 2022 Aug 5;17(8):e0272426
pubmed: 35930557
PLoS One. 2022 May 19;17(5):e0267580
pubmed: 35587462
J Health Commun. 2020 Oct 2;25(10):838-842
pubmed: 33719882
Cochrane Database Syst Rev. 2020 Jan 17;1:CD011895
pubmed: 31978259
Nat Rev Microbiol. 2021 Jul;19(7):406
pubmed: 34017089
JBI Evid Synth. 2020 Oct;18(10):2119-2126
pubmed: 33038124
Am J Transplant. 2021 Apr;21(4):1650-1656
pubmed: 33788992
J Law Biosci. 2021 Sep 06;8(2):lsab027
pubmed: 34512996
J Med Libr Assoc. 2006 Oct;94(4):451-5
pubmed: 17082841
Psychol Med. 2020 Dec 11;:1-15
pubmed: 33305716
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34413212
Lancet Public Health. 2021 Jun;6(6):e416-e427
pubmed: 33991482
Nat Hum Behav. 2021 Mar;5(3):337-348
pubmed: 33547453
Health Commun. 2021 Sep 20;:1-11
pubmed: 34544315
Int J Health Policy Manag. 2021 Jan 18;:
pubmed: 33619928
J Health Econ. 2022 Jan;81:102578
pubmed: 34986437
Ecohealth. 2021 Mar;18(1):44-60
pubmed: 34086129
JAMA Netw Open. 2021 Sep 1;4(9):e2126635
pubmed: 34591105
Int J Environ Res Public Health. 2021 Aug 20;18(16):
pubmed: 34444549
JAMA Oncol. 2021 Oct 1;7(10):1570-1572
pubmed: 34410323
Elife. 2022 Aug 16;11:
pubmed: 35971757
Public Health. 2021 Dec;201:98-107
pubmed: 34801843
Vaccines (Basel). 2022 Jan 04;10(1):
pubmed: 35062738
Health Commun. 2021 Sep 2;:1-10
pubmed: 34474607
AIDS Behav. 2020 Oct;24(10):2776-2780
pubmed: 32440972
Psychol Med. 2021 Sep 20;:1-3
pubmed: 34538287
PLoS One. 2021 Mar 24;16(3):e0248892
pubmed: 33760836
Patient Educ Couns. 2022 Feb;105(2):284-289
pubmed: 34479746
JAMA. 2021 Aug 24;326(8):766-767
pubmed: 34213530
Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):
pubmed: 33443183
Am J Med. 2021 Nov;134(11):1424-1426
pubmed: 34339676
Vaccine. 2015 Aug 14;33(34):4180-90
pubmed: 25896377
Hum Vaccin Immunother. 2015;11(1):72-82
pubmed: 25483518
Appl Psychol Health Well Being. 2021 Nov;13(4):986-995
pubmed: 34032388
BMC Med Res Methodol. 2018 Nov 19;18(1):143
pubmed: 30453902
PLoS One. 2022 Jan 24;17(1):e0260949
pubmed: 35073312
Soc Sci Med. 2021 Nov;289:114416
pubmed: 34562773
Hum Vaccin Immunother. 2021 Sep 2;17(9):2940-2945
pubmed: 33998949
Cochrane Database Syst Rev. 2018 May 08;5:CD010038
pubmed: 29736980
Soc Sci Med. 2020 Oct;263:113356
pubmed: 32967786
J Health Commun. 2021 Sep 2;26(9):608-617
pubmed: 34596481
Hum Vaccin Immunother. 2021 Sep 2;17(9):2894-2902
pubmed: 33877955
Eur J Epidemiol. 2021 Jul;36(7):709-714
pubmed: 34037927
PLoS One. 2021 Oct 28;16(10):e0259059
pubmed: 34710168
Cochrane Database Syst Rev. 2022 Aug 3;8:CD015270
pubmed: 35920693
Vaccines (Basel). 2021 Sep 30;9(10):
pubmed: 34696221
Vaccines (Basel). 2021 May 24;9(6):
pubmed: 34073757
Int J Environ Res Public Health. 2021 Apr 28;18(9):
pubmed: 33924796
Vaccines (Basel). 2021 Feb 16;9(2):
pubmed: 33669441
Vaccine. 2021 Jan 29;39(5):825-829
pubmed: 33390295
BMC Med Inform Decis Mak. 2021 Jul 31;21(1):228
pubmed: 34332570
JAMA Netw Open. 2021 Jul 1;4(7):e2118702
pubmed: 34319359
Eur J Intern Med. 2021 May;87:106-108
pubmed: 33810941
Science. 2021 Nov 12;374(6569):879-882
pubmed: 34618594
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
Health Res Policy Syst. 2008 Jul 09;6:7
pubmed: 18613961
J Med Ethics. 2021 Aug;47(8):547-548
pubmed: 33602717
Health Psychol. 2015 Feb;34(2):160-71
pubmed: 25133822
EClinicalMedicine. 2021 May 15;35:100881
pubmed: 34124631
medRxiv. 2021 Feb 28;:
pubmed: 33655271
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1201-1206
pubmed: 34287112
Proc Natl Acad Sci U S A. 2021 Mar 9;118(10):
pubmed: 33619178
Vaccines (Basel). 2021 Sep 07;9(9):
pubmed: 34579232
Vaccine. 2014 Apr 17;32(19):2150-9
pubmed: 24598724
Int J Environ Res Public Health. 2021 Sep 08;18(18):
pubmed: 34574406
J Community Health. 2021 Dec;46(6):1155-1160
pubmed: 33988777
Health Psychol. 2022 Feb;41(2):85-93
pubmed: 34570535
Int J Clin Pract. 2021 Apr;75(4):e13891
pubmed: 33278857
J Health Commun. 2021 Aug 3;26(8):523-533
pubmed: 34424140
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Vaccines (Basel). 2021 May 17;9(5):
pubmed: 34067682
Trials. 2021 Apr 29;22(1):311
pubmed: 33926540
Value Health. 2021 Nov;24(11):1543-1550
pubmed: 34711354
PLoS One. 2021 Sep 27;16(9):e0257988
pubmed: 34570798
NPJ Vaccines. 2021 May 14;6(1):73
pubmed: 33990614
JMIR Res Protoc. 2021 May 13;:
pubmed: 34086594
Health Commun. 2021 Jun 11;:1-8
pubmed: 34114897
PLoS One. 2020 May 14;15(5):e0232652
pubmed: 32407329
Pan Afr Med J. 2021 Jan 05;38:3
pubmed: 33520072
Cochrane Database Syst Rev. 2018 May 30;5:CD005188
pubmed: 29845606
Vacunas. 2021 May-Aug;22(2):93-97
pubmed: 33727904
Vaccines (Basel). 2021 Apr 13;9(4):
pubmed: 33924534
J Exp Psychol Appl. 2021 Dec;27(4):669-678
pubmed: 34292048
J Public Health (Oxf). 2022 Mar 7;44(1):e106-e116
pubmed: 33948665
Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):
pubmed: 34312254
Psychol Sci Public Interest. 2017 Dec;18(3):149-207
pubmed: 29611455
Nat Hum Behav. 2021 Mar;5(3):407
pubmed: 33686205
Vaccine. 2022 Jul 30;40(32):4654-4662
pubmed: 35750541
PLoS One. 2021 Sep 20;16(9):e0257111
pubmed: 34543291
Pediatrics. 2014 Oct;134(4):e1117-28
pubmed: 25225138
Cochrane Database Syst Rev. 2016 Jul 10;7:CD008145
pubmed: 27394698
Vaccines (Basel). 2021 Jul 07;9(7):
pubmed: 34358173
Ann Behav Med. 2022 Apr 2;56(4):325-331
pubmed: 34398184
Syst Dyn Rev. 2022 Jul-Sep;38(3):246-263
pubmed: 36245852
BMJ. 2021 May 13;373:n1088
pubmed: 33985964
Cochrane Database Syst Rev. 2018 Jan 18;1:CD003941
pubmed: 29342498
Public Health. 2021 May;194:245-251
pubmed: 33965796
Hum Vaccin Immunother. 2021 Oct 3;17(10):3450-3456
pubmed: 34128754
Am J Manag Care. 2007 Oct;13(10):581-8
pubmed: 17927463
Lancet Public Health. 2021 Apr;6(4):e210-e221
pubmed: 33556325
Proc Natl Acad Sci U S A. 2021 Aug 10;118(32):
pubmed: 34315824
Vaccines (Basel). 2021 Apr 13;9(4):
pubmed: 33924542
Br J Health Psychol. 2022 May;27(2):300-319
pubmed: 34250684
PLoS One. 2022 Mar 30;17(3):e0263425
pubmed: 35353815
Nature. 2021 Sep;597(7876):404-409
pubmed: 34340242
PLoS One. 2022 Jan 19;17(1):e0258828
pubmed: 35045071
Trials. 2021 Sep 06;22(1):592
pubmed: 34488843
Health Educ Res. 2011 Apr;26(2):192-200
pubmed: 21106651
Hum Vaccin Immunother. 2021 Aug 3;17(8):2415-2420
pubmed: 34014128
Healthcare (Basel). 2021 Mar 19;9(3):
pubmed: 33808758

Auteurs

Marike Andreas (M)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Claire Iannizzi (C)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Emma Bohndorf (E)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Ina Monsef (I)

Faculty of Medicine and University Hospital Cologne, University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cochrane Haematology, Cologne, Germany.

Vanessa Piechotta (V)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Joerg J Meerpohl (JJ)

Institute for Evidence in Medicine (for Cochrane Germany Foundation), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Nicole Skoetz (N)

Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH